J&J’s DePuy Synthes announces limited launch of Attune cementless knee
Johnson & Johnson’s (NYSE:JNJ) DePuy Synthesis division said today it is launching the Attune cementless knee in a rotating platform option in select markets around the world.
This launch combines the proprietary technologies of the Attune knee designed to provide stability while the knee is in motion with DePuy Synthes’ background in rotating platform knees and cementless technology.
“The Attune cementless knee has the same great kinematic features of the cemented Attune knee, but I feel the cementless technology is a better alternative for my younger and more active patients who have healthy, strong bone,” said Dr. Ryan M. Nunley, associate professor and fellowship director at Washington University Orthopedics, Barnes Jewish Hospital, said in a news release. “These patients have the potential to remain active for many decades, and I think the evidence is growing that cementless knees have good long-term durability. I’ve implanted more than 400 Attune cementless knees in my practice with excellent early results.”
The Attune cementless knee’s patented technologies, designed to improve knee function, include the Attune Gradius Curve to provide stability through the range of motion and GlideRight articulation to more accurately replicate the normal relationship between the patella (knee cap) and femur.
“With the Attune cementless knee, we have carried forward technologies and learnings from clinically proven devices like the LCS Knee and combined that with Attune knee patented technologies to provide our customers a compelling solution to meeting emerging patient needs,” said Rajit Kamal, VP & global franchise leader for knees at DePuy Synthes. “Our strong hope and belief are that this implant system will help younger, more active patients get back to doing what they love if their surgeon feels they are the right candidate.”
DePuy Synthes is initially launching the Attune cementless knee in the United States, select countries in Europe, Japan, Australia and New Zealand, with additional launches to follow. It is available in a cruciate-retaining and posterior-stabilized rotating platform construct as well as a hybrid construct (cementless femoral component with a cemented fixed bearing or rotating platform tibial base).